Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.

Arrowaili A

Obesity surgery16 Apr 2025Cited by 5 (Europe PMC)

PMID40237975DOI10.1007/s11695-025-07856-yPepBankPUB-40237975

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with weight recurrence or suboptimal response after metabolic bariatric surgery, the pooled liraglutide/semaglutide/tirzepatide synthesis reported decreased weight with positive MD 8.07 kg (95% CI 5.5 to 10.64; P<0.00001; I2=44%, heterogeneity P=0.04); the original contrast orientation was unstated.
In plain wordsAfter bariatric surgery with weight recurrence or suboptimal response, pooled drugs including liraglutide were linked to lower weight; comparison orientation was unspecified.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Printed weight MD
8.07 kg
positive estimate as printed; original reference/orientation unstated
95% CI
5.5 to 10.64 kg
printed weight MD
P-value
< 0.00001
weight result
I2
44%
weight synthesis
Heterogeneity P-value
0.04
weight synthesis
Source sentences
Summary
The use of GLP- 1 agonists (liraglutide, semaglutide, and tirzepatide) was associated with a statistically significant decrease in the weight of the included patients showing an overall MD = 8.07 kg (95%CI: 5.5, 10.64, p 2 = 44%, p = 0.04.
2 context sentences(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we aimed to pool the results from all available studies on GLP- 1 agonists to assess the efficacy of these drugs in weight recurrence or suboptimal clinical response of patients who underwent MBS.
Summary · context
We searched PubMed, Scopus, and Web of Science from inception till October 2024 for articles that fulfil our eligibility to be included in the systematic review and meta-analysis investigating the use of GLP- 1 agonists in the management of weight recurrence or suboptimal clinical response in patien…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4023797501
02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients with weight recurrence or suboptimal response after metabolic bariatric surgery, the pooled liraglutide/semaglutide/tirzepatide synthesis reported decreased weight with positive MD 8.07 kg (95% CI 5.5 to 10.64; P<0.00001; I2=44%, heterogeneity P=0.04); the original contrast orientation was unstated.
In plain wordsAfter bariatric surgery with weight recurrence or suboptimal response, pooled drugs including semaglutide were linked to lower weight; comparison orientation was unspecified.
Peptide
Semaglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Printed weight MD
8.07 kg
positive estimate as printed; original reference/orientation unstated
95% CI
5.5 to 10.64 kg
printed weight MD
P-value
< 0.00001
weight result
I2
44%
weight synthesis
Heterogeneity P-value
0.04
weight synthesis
Source sentences
Summary
The use of GLP- 1 agonists (liraglutide, semaglutide, and tirzepatide) was associated with a statistically significant decrease in the weight of the included patients showing an overall MD = 8.07 kg (95%CI: 5.5, 10.64, p 2 = 44%, p = 0.04.
2 context sentences(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we aimed to pool the results from all available studies on GLP- 1 agonists to assess the efficacy of these drugs in weight recurrence or suboptimal clinical response of patients who underwent MBS.
Summary · context
We searched PubMed, Scopus, and Web of Science from inception till October 2024 for articles that fulfil our eligibility to be included in the systematic review and meta-analysis investigating the use of GLP- 1 agonists in the management of weight recurrence or suboptimal clinical response in patien…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4023797502
03HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In patients with weight recurrence or suboptimal response after metabolic bariatric surgery, the pooled liraglutide/semaglutide/tirzepatide synthesis reported decreased weight with positive MD 8.07 kg (95% CI 5.5 to 10.64; P<0.00001; I2=44%, heterogeneity P=0.04); the original contrast orientation was unstated.
In plain wordsAfter bariatric surgery with weight recurrence or suboptimal response, pooled drugs including tirzepatide were linked to lower weight; comparison orientation was unspecified.
Peptide
Tirzepatide
Outcome
DecreaseBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Printed weight MD
8.07 kg
positive estimate as printed; original reference/orientation unstated
95% CI
5.5 to 10.64 kg
printed weight MD
P-value
< 0.00001
weight result
I2
44%
weight synthesis
Heterogeneity P-value
0.04
weight synthesis
Source sentences
Summary
The use of GLP- 1 agonists (liraglutide, semaglutide, and tirzepatide) was associated with a statistically significant decrease in the weight of the included patients showing an overall MD = 8.07 kg (95%CI: 5.5, 10.64, p 2 = 44%, p = 0.04.
2 context sentences(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we aimed to pool the results from all available studies on GLP- 1 agonists to assess the efficacy of these drugs in weight recurrence or suboptimal clinical response of patients who underwent MBS.
Summary · context
We searched PubMed, Scopus, and Web of Science from inception till October 2024 for articles that fulfil our eligibility to be included in the systematic review and meta-analysis investigating the use of GLP- 1 agonists in the management of weight recurrence or suboptimal clinical response in patien…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4023797503
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with weight recurrence or suboptimal response after metabolic bariatric surgery, pooled liraglutide/semaglutide evidence reported decreased BMI after treatment with positive MD 4.42 kg/m2 (95% CI 3.42 to 5.42; P<0.00001; I2=67%, heterogeneity P=0.0005); contrast orientation was unstated.
In plain wordsAfter bariatric surgery with weight recurrence or suboptimal response, pooled liraglutide/semaglutide treatment was linked to lower BMI; comparison orientation was unspecified.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Printed BMI MD
4.42 kg/m2
positive estimate as printed; original reference/orientation unstated
95% CI
3.42 to 5.42 kg/m2
printed BMI MD
P-value
< 0.00001
BMI result
I2
67%
BMI synthesis
Heterogeneity P-value
0.0005
BMI synthesis
Source sentences
Summary
Moreover, these drugs (liraglutide, and semaglutide) showed significantly reduced body mass index (BMI) after treatment with overall MD = 4.42 kg/m² (95%CI: 3.42, 5.42, p 2 = 67%, p = 0.0005.
2 context sentences(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we aimed to pool the results from all available studies on GLP- 1 agonists to assess the efficacy of these drugs in weight recurrence or suboptimal clinical response of patients who underwent MBS.
Summary · context
We searched PubMed, Scopus, and Web of Science from inception till October 2024 for articles that fulfil our eligibility to be included in the systematic review and meta-analysis investigating the use of GLP- 1 agonists in the management of weight recurrence or suboptimal clinical response in patien…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4023797504
05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients with weight recurrence or suboptimal response after metabolic bariatric surgery, pooled liraglutide/semaglutide evidence reported decreased BMI after treatment with positive MD 4.42 kg/m2 (95% CI 3.42 to 5.42; P<0.00001; I2=67%, heterogeneity P=0.0005); contrast orientation was unstated.
In plain wordsAfter bariatric surgery with weight recurrence or suboptimal response, pooled liraglutide/semaglutide treatment was linked to lower BMI; comparison orientation was unspecified.
Peptide
Semaglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Printed BMI MD
4.42 kg/m2
positive estimate as printed; original reference/orientation unstated
95% CI
3.42 to 5.42 kg/m2
printed BMI MD
P-value
< 0.00001
BMI result
I2
67%
BMI synthesis
Heterogeneity P-value
0.0005
BMI synthesis
Source sentences
Summary
Moreover, these drugs (liraglutide, and semaglutide) showed significantly reduced body mass index (BMI) after treatment with overall MD = 4.42 kg/m² (95%CI: 3.42, 5.42, p 2 = 67%, p = 0.0005.
2 context sentences(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we aimed to pool the results from all available studies on GLP- 1 agonists to assess the efficacy of these drugs in weight recurrence or suboptimal clinical response of patients who underwent MBS.
Summary · context
We searched PubMed, Scopus, and Web of Science from inception till October 2024 for articles that fulfil our eligibility to be included in the systematic review and meta-analysis investigating the use of GLP- 1 agonists in the management of weight recurrence or suboptimal clinical response in patien…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4023797505
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with weight recurrence or suboptimal response after metabolic bariatric surgery, pooled liraglutide/semaglutide/tirzepatide treatment was associated with lower weight versus control (MD -9.19%, 95% CI -10.81 to -7.58; P<0.00001; I2=0%).
In plain wordsAfter bariatric surgery with weight recurrence or suboptimal response, pooled drugs including liraglutide were linked to lower weight than control.
Peptide
Liraglutide
Outcome
DecreaseWeight versus control
Study
n: not reported in source
Comparator
Control group
Outcome group
Body weight · Metabolic and weight
Measurements
Weight MD
−9.19%
pooled drugs versus control
95% CI
−10.81 to −7.58%
weight MD versus control
P-value
< 0.00001
weight versus control
I2
0%
weight versus control
Source sentences
Summary
Compared with control group, the use of GLP- 1 agonists was associated with reduced weight with MD = - 9.19% (95%CI: - 10.81, - 7.58, p 2 = 0%.
2 context sentences(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we aimed to pool the results from all available studies on GLP- 1 agonists to assess the efficacy of these drugs in weight recurrence or suboptimal clinical response of patients who underwent MBS.
Summary · context
We searched PubMed, Scopus, and Web of Science from inception till October 2024 for articles that fulfil our eligibility to be included in the systematic review and meta-analysis investigating the use of GLP- 1 agonists in the management of weight recurrence or suboptimal clinical response in patien…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4023797506
07HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients with weight recurrence or suboptimal response after metabolic bariatric surgery, pooled liraglutide/semaglutide/tirzepatide treatment was associated with lower weight versus control (MD -9.19%, 95% CI -10.81 to -7.58; P<0.00001; I2=0%).
In plain wordsAfter bariatric surgery with weight recurrence or suboptimal response, pooled drugs including semaglutide were linked to lower weight than control.
Peptide
Semaglutide
Outcome
DecreaseWeight versus control
Study
n: not reported in source
Comparator
Control group
Outcome group
Body weight · Metabolic and weight
Measurements
Weight MD
−9.19%
pooled drugs versus control
95% CI
−10.81 to −7.58%
weight MD versus control
P-value
< 0.00001
weight versus control
I2
0%
weight versus control
Source sentences
Summary
Compared with control group, the use of GLP- 1 agonists was associated with reduced weight with MD = - 9.19% (95%CI: - 10.81, - 7.58, p 2 = 0%.
2 context sentences(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we aimed to pool the results from all available studies on GLP- 1 agonists to assess the efficacy of these drugs in weight recurrence or suboptimal clinical response of patients who underwent MBS.
Summary · context
We searched PubMed, Scopus, and Web of Science from inception till October 2024 for articles that fulfil our eligibility to be included in the systematic review and meta-analysis investigating the use of GLP- 1 agonists in the management of weight recurrence or suboptimal clinical response in patien…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4023797507
08HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In patients with weight recurrence or suboptimal response after metabolic bariatric surgery, pooled liraglutide/semaglutide/tirzepatide treatment was associated with lower weight versus control (MD -9.19%, 95% CI -10.81 to -7.58; P<0.00001; I2=0%).
In plain wordsAfter bariatric surgery with weight recurrence or suboptimal response, pooled drugs including tirzepatide were linked to lower weight than control.
Peptide
Tirzepatide
Outcome
DecreaseWeight versus control
Study
n: not reported in source
Comparator
Control group
Outcome group
Body weight · Metabolic and weight
Measurements
Weight MD
−9.19%
pooled drugs versus control
95% CI
−10.81 to −7.58%
weight MD versus control
P-value
< 0.00001
weight versus control
I2
0%
weight versus control
Source sentences
Summary
Compared with control group, the use of GLP- 1 agonists was associated with reduced weight with MD = - 9.19% (95%CI: - 10.81, - 7.58, p 2 = 0%.
2 context sentences(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we aimed to pool the results from all available studies on GLP- 1 agonists to assess the efficacy of these drugs in weight recurrence or suboptimal clinical response of patients who underwent MBS.
Summary · context
We searched PubMed, Scopus, and Web of Science from inception till October 2024 for articles that fulfil our eligibility to be included in the systematic review and meta-analysis investigating the use of GLP- 1 agonists in the management of weight recurrence or suboptimal clinical response in patien…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4023797508
09HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with weight recurrence or suboptimal response after metabolic bariatric surgery, pooled liraglutide/semaglutide/tirzepatide treatment showed no significant BMI-change difference versus control (MD -1.97%, 95% CI -4.65 to 0.71; P=0.15).
In plain wordsAfter bariatric surgery with weight recurrence or suboptimal response, pooled drugs including liraglutide showed no significant BMI-change difference from control.
Peptide
Liraglutide
Outcome
No significant changeBody mass index change versus control
Study
n: not reported in source
Comparator
Control group
Outcome group
Body weight · Metabolic and weight
Measurements
BMI-change MD
−1.97%
pooled drugs versus control
95% CI
−4.65 to 0.71%
BMI change versus control
P-value
0.15
BMI versus control
Source sentences
Summary
However, no difference was observed between both groups regarding BMI change with MD = - 1.97% (95%CI: - 4.65, 0.71, p = 0.15).
2 context sentences(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we aimed to pool the results from all available studies on GLP- 1 agonists to assess the efficacy of these drugs in weight recurrence or suboptimal clinical response of patients who underwent MBS.
Summary · context
We searched PubMed, Scopus, and Web of Science from inception till October 2024 for articles that fulfil our eligibility to be included in the systematic review and meta-analysis investigating the use of GLP- 1 agonists in the management of weight recurrence or suboptimal clinical response in patien…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4023797509
10HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients with weight recurrence or suboptimal response after metabolic bariatric surgery, pooled liraglutide/semaglutide/tirzepatide treatment showed no significant BMI-change difference versus control (MD -1.97%, 95% CI -4.65 to 0.71; P=0.15).
In plain wordsAfter bariatric surgery with weight recurrence or suboptimal response, pooled drugs including semaglutide showed no significant BMI-change difference from control.
Peptide
Semaglutide
Outcome
No significant changeBody mass index change versus control
Study
n: not reported in source
Comparator
Control group
Outcome group
Body weight · Metabolic and weight
Measurements
BMI-change MD
−1.97%
pooled drugs versus control
95% CI
−4.65 to 0.71%
BMI change versus control
P-value
0.15
BMI versus control
Source sentences
Summary
However, no difference was observed between both groups regarding BMI change with MD = - 1.97% (95%CI: - 4.65, 0.71, p = 0.15).
2 context sentences(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we aimed to pool the results from all available studies on GLP- 1 agonists to assess the efficacy of these drugs in weight recurrence or suboptimal clinical response of patients who underwent MBS.
Summary · context
We searched PubMed, Scopus, and Web of Science from inception till October 2024 for articles that fulfil our eligibility to be included in the systematic review and meta-analysis investigating the use of GLP- 1 agonists in the management of weight recurrence or suboptimal clinical response in patien…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4023797510
11HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In patients with weight recurrence or suboptimal response after metabolic bariatric surgery, pooled liraglutide/semaglutide/tirzepatide treatment showed no significant BMI-change difference versus control (MD -1.97%, 95% CI -4.65 to 0.71; P=0.15).
In plain wordsAfter bariatric surgery with weight recurrence or suboptimal response, pooled drugs including tirzepatide showed no significant BMI-change difference from control.
Peptide
Tirzepatide
Outcome
No significant changeBody mass index change versus control
Study
n: not reported in source
Comparator
Control group
Outcome group
Body weight · Metabolic and weight
Measurements
BMI-change MD
−1.97%
pooled drugs versus control
95% CI
−4.65 to 0.71%
BMI change versus control
P-value
0.15
BMI versus control
Source sentences
Summary
However, no difference was observed between both groups regarding BMI change with MD = - 1.97% (95%CI: - 4.65, 0.71, p = 0.15).
2 context sentences(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we aimed to pool the results from all available studies on GLP- 1 agonists to assess the efficacy of these drugs in weight recurrence or suboptimal clinical response of patients who underwent MBS.
Summary · context
We searched PubMed, Scopus, and Web of Science from inception till October 2024 for articles that fulfil our eligibility to be included in the systematic review and meta-analysis investigating the use of GLP- 1 agonists in the management of weight recurrence or suboptimal clinical response in patien…
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4023797511

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.